Profile data is unavailable for this security.
About the company
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells. The Company's platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body's intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its two oncology drug product candidates, CUE-101 and CUE-102, are exemplary programs from the interleukin 2 (IL-2) based CUE-100 series, and are representative of the HLA-A02 allele, which is prevalent in the United States and western European territories. CUE-101 HLA-A02 is engineered for the treatment of human papillomavirus positive, head and neck squamous cell carcinoma (HNSCC). CUE-102 HLA-A02, targeting Wilms' Tumor 1 protein, an oncofetal antigen known to be over-expressed in more than 20 different cancers.
- Revenue in USD (TTM)7.02m
- Net income in USD-49.97m
- Incorporated2014
- Employees53.00
- LocationCue Biopharma Inc40 Guest StreetBOSTON 02135United StatesUSA
- Phone+1 (617) 949-2680
- Fax+1 (302) 655-5049
- Websitehttps://www.cuebiopharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assembly Biosciences Inc | 12.95m | -51.36m | 81.32m | 65.00 | -- | 2.48 | -- | 6.28 | -11.22 | -11.22 | 2.76 | 5.95 | 0.1276 | -- | 34.07 | 199,200.00 | -50.60 | -39.69 | -66.58 | -44.03 | -- | -- | -396.63 | -409.24 | -- | -- | 0.00 | -- | -- | -13.51 | 34.23 | -- | -5.59 | -- |
| NDT Pharmaceuticals Inc | -100.00bn | -100.00bn | 81.60m | 1.00 | -- | 0.4556 | -- | -- | -- | -- | -- | 1.12 | -- | -- | -- | -- | -- | -164.47 | -- | -452.47 | -- | -- | -- | -6,891.36 | -- | -- | 0.00 | -- | -100.00 | -- | 87.56 | -- | -- | -- |
| Maia Biotechnology Inc | 0.00 | -23.72m | 83.20m | 13.00 | -- | -- | -- | -- | -1.57 | -1.57 | 0.00 | -0.2801 | 0.00 | -- | -- | 0.00 | -266.70 | -- | -520.49 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -21.91 | -- | -- | -- |
| Aclaris Therapeutics Inc | 31.12m | -77.26m | 84.09m | 91.00 | -- | 0.592 | -- | 2.70 | -1.09 | -1.09 | 0.4392 | 1.99 | 0.1541 | -- | 58.77 | 341,967.00 | -38.27 | -47.29 | -42.29 | -53.87 | 41.99 | 44.00 | -248.28 | -549.18 | -- | -- | 0.00 | -- | 5.03 | 38.41 | -1.81 | -- | -0.703 | -- |
| Chimerix Inc | 41.00k | -82.59m | 84.45m | 72.00 | -- | 0.4851 | -- | 2,059.74 | -0.9296 | -0.9296 | 0.0005 | 1.94 | 0.0002 | -- | 0.1226 | 569.44 | -36.50 | -30.45 | -39.59 | -34.09 | 100.00 | -- | -201,443.90 | -442.93 | -- | -- | 0.00 | -- | -99.04 | -46.24 | -147.68 | -- | -13.24 | -- |
| SCYNEXIS Inc | 140.39m | 101.33m | 84.63m | 29.00 | 1.11 | 1.14 | -- | 0.6028 | 2.01 | 2.01 | 2.89 | 1.96 | 1.49 | -- | 136.30 | 4,840,862.00 | 107.48 | -30.02 | 175.37 | -36.35 | 88.97 | -- | 72.18 | -86.76 | -- | 193.81 | 0.1433 | -- | 2,652.72 | 252.64 | 206.74 | -- | -- | -- |
| Cue Biopharma Inc | 7.02m | -49.97m | 84.64m | 53.00 | -- | 2.82 | -- | 12.06 | -1.07 | -1.07 | 0.1495 | 0.6175 | 0.1035 | -- | 8.80 | 132,452.80 | -73.69 | -57.45 | -96.35 | -68.41 | -- | -- | -711.84 | -810.87 | -- | -- | 0.1935 | -- | 340.88 | 36.88 | 4.30 | -- | -- | -- |
| Anixa Biosciences Inc | 210.00k | -10.74m | 84.85m | 4.00 | -- | 3.43 | -- | 404.06 | -0.3451 | -0.3451 | 0.0068 | 0.7749 | 0.0078 | -- | 0.7807 | 52,500.00 | -40.49 | -59.69 | -41.26 | -62.61 | -- | -- | -5,174.29 | -6,040.10 | -- | -- | 0.00 | -- | -- | -28.36 | 27.83 | -- | -- | -- |
| Allovir Inc | 0.00 | -179.53m | 85.85m | 112.00 | -- | 0.712 | -- | -- | -1.65 | -1.65 | 0.00 | 1.05 | 0.00 | -- | -- | 0.00 | -92.50 | -52.85 | -100.98 | -57.72 | -- | -- | -- | -378,613.90 | -- | -- | 0.00 | -- | -- | -- | -12.87 | -- | -- | -- |
| IO Biotech Inc | 0.00 | -88.50m | 86.96m | 68.00 | -- | 0.7532 | -- | -- | -1.86 | -1.86 | 0.00 | 1.75 | 0.00 | -- | -- | 0.00 | -66.79 | -- | -72.66 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.47 | -- | -- | -- |
| vTv Therapeutics Inc | 1.00m | -20.62m | 86.99m | 16.00 | -- | 4.18 | -- | 86.99 | -8.76 | -8.76 | 0.383 | 6.91 | 0.0241 | -- | 2.04 | 62,500.00 | -63.15 | -111.84 | -128.59 | -- | -- | -- | -2,621.10 | -680.94 | -- | -- | 0.00 | -- | -100.00 | -- | -5.67 | -- | -- | -- |
| Benitec Biopharma Inc | 7.00k | -21.69m | 88.15m | 18.00 | -- | 2.23 | -- | 12,592.58 | -9.87 | -9.87 | 0.0031 | 4.22 | 0.0006 | -- | 0.1284 | 388.89 | -186.85 | -83.43 | -260.89 | -98.77 | 1,542.86 | 96.86 | -309,885.70 | -468.04 | -- | -307.03 | 0.00 | -- | 2.74 | -53.84 | -7.44 | -- | -56.51 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Bleichroeder LPas of 31 Mar 2024 | 2.76m | 5.66% |
| Slate Path Capital LPas of 31 Mar 2024 | 2.40m | 4.94% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 2.21m | 4.55% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 2.08m | 4.27% |
| Geode Capital Management LLCas of 31 Mar 2024 | 838.53k | 1.72% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 759.80k | 1.56% |
| Robertson Stephens Wealth Management LLC (Invt Mgmt)as of 31 Mar 2024 | 478.50k | 0.98% |
| Dimensional Fund Advisors LPas of 31 Mar 2024 | 431.31k | 0.89% |
| Millennium Management LLCas of 31 Mar 2024 | 362.09k | 0.74% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 345.32k | 0.71% |
